the whole object this page is drawn from, as JSON · Open JSON {
"id": "atm_ovt_4ed8fba5_1877_4293_96e6_512cebed39be",
"kind": "LocalBusiness",
"name": "Aulos Bioscience, Inc.",
"parent_id": "atm_geoid_060411212002012",
"depth": null,
"facts": {
"phones": [
"+18603842879"
],
"address": "700 Larkspur Landing Cir Ste 108",
"sources": [
{
"between": null,
"dataset": "BrightQuery",
"license": "CDLA-Permissive-2.0",
"version": "2026-09-08",
"property": "",
"provider": "brightquery",
"resource": "brightquery",
"record_id": "384995914",
"confidence": 0.95,
"update_time": "2026-09-17T20:01:51.007Z"
},
{
"between": null,
"dataset": "Overture",
"license": "CDLA-Permissive-2.0",
"version": "2026-09-17",
"property": "/properties/confidence",
"provider": "overture",
"resource": "confidence_calculation",
"record_id": null,
"confidence": null,
"update_time": "2026-09-17T22:52:12Z"
}
],
"category": "b2b_scientific_lab",
"locality": "Larkspur",
"postcode": "94939-1710",
"websites": [
"https://aulosbio.com/"
],
"hierarchy": [
"services_and_business",
"b2b_service",
"b2b_science_and_technology_service",
"b2b_scientific_lab"
],
"confidence": 0.95,
"overture_id": "4ed8fba5-1877-4293-96e6-512cebed39be",
"basic_category": "b2b_science_and_technology_service",
"operating_status": "open",
"overture_release": "2026-09-23.1"
},
"source_id": "src_ea62d6013cef6e1e92b7",
"updated_at": "2026-10-10T02:27:42.226Z",
"type": "Feature",
"geometry": {
"type": "Point",
"coordinates": [
-122.511354,
37.948278
]
},
"links": {
"self": "https://miscsubjects.com/atlas/atoms/atm_ovt_4ed8fba5_1877_4293_96e6_512cebed39be",
"children": "https://miscsubjects.com/atlas/atoms/atm_ovt_4ed8fba5_1877_4293_96e6_512cebed39be/children",
"descendants": "https://miscsubjects.com/atlas/atoms/atm_ovt_4ed8fba5_1877_4293_96e6_512cebed39be/descendants",
"inside": "https://miscsubjects.com/atlas/atoms/atm_ovt_4ed8fba5_1877_4293_96e6_512cebed39be/inside",
"graph": "https://miscsubjects.com/atlas/graph?start=atm_ovt_4ed8fba5_1877_4293_96e6_512cebed39be"
},
"ancestors": [
{
"id": "atm_geoid_060411212002012",
"kind": "CensusBlock",
"name": "Block 2012",
"up": 1
},
{
"id": "atm_geoid_060411212002",
"kind": "CensusBlockGroup",
"name": "Block Group 2",
"up": 2
},
{
"id": "atm_geoid_06041121200",
"kind": "CensusTract",
"name": "Census Tract 1212",
"up": 3
},
{
"id": "atm_geoid_06041",
"kind": "County",
"name": "Marin County",
"up": 4
},
{
"id": "atm_geoid_06",
"kind": "State",
"name": "California",
"up": 5
},
{
"id": "atm_geoid_us",
"kind": "Country",
"name": "United States",
"up": 6
}
],
"children_by_kind": [],
"edges_out": [
{
"rel": "has_profile",
"id": "atm_prof_15ce4aaf10e5c20e0751",
"kind": "Profile",
"name": "x: aulosbioscience",
"share": null
},
{
"rel": "has_profile",
"id": "atm_prof_c14bf20f784ee21b1eb0",
"kind": "Profile",
"name": "linkedin: company/aulos-bioscience",
"share": null
},
{
"rel": "has_profile",
"id": "atm_prof_ceaf82740271fd118989",
"kind": "Profile",
"name": "linkedin: company/aulos-bioscience",
"share": null
},
{
"rel": "has_website",
"id": "atm_public_page_cff5f1192890b83edc4127b5",
"kind": "WebPage",
"name": "https://aulosbio.com/",
"share": null
}
],
"edges_in": [
{
"rel": "site_of",
"id": "atm_site_a362fad4f6d9cc7263ac",
"kind": "Website",
"name": "Aulos Bioscience",
"share": null
}
],
"edges_in_total": 1,
"external_ids": [
{
"system": "overture_gers",
"value": "4ed8fba5-1877-4293-96e6-512cebed39be"
}
],
"source": {
"id": "src_ea62d6013cef6e1e92b7",
"url": null,
"license": "Overture Maps Foundation 2026-09-23.1: places CDLA-Permissive 2.0 / ODbL for OSM-derived; buildings and addresses ODbL / CDLA-P; divisions and transportation ODbL (https://docs.overturemaps.org/attribution/)",
"read_at": "2026-10-10T02:27:22.458Z",
"sha256": "af0a59a33d2a75cacc7cf95f854d2f1af02bfaffbfc955875480f1b30e380665"
},
"observations": [
{
"service": "WEBSITE_EXTRACT",
"fetched_at": {},
"query": {
"job": "website:atm_ovt_4ed8fba5_1877_4293_96e6_512cebed39be",
"url": "https://aulosbio.com/"
},
"payload": {
"title": "Revolutionizing cancer care through IL2 therapeutics | Aulos Bioscience",
"emails": [
"ajax-loader@2x.gif"
],
"jsonld": [
{
"@graph": [
{
"@id": "https://aulosbio.com/",
"url": "https://aulosbio.com/",
"name": "Revolutionizing cancer care through IL2 therapeutics | Aulos Bioscience",
"@type": "WebPage",
"isPartOf": {
"@id": "https://aulosbio.com/#website"
},
"breadcrumb": {
"@id": "https://aulosbio.com/#breadcrumb"
},
"inLanguage": "en-US",
"description": "Aulos Bioscience is a immuno-oncology company revolutionizing cancer care through the development of best-in-class IL-2 therapeutics. Learn more.",
"dateModified": "2026-05-31T12:00:28+00:00",
"datePublished": "2021-10-26T15:21:09+00:00",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://aulosbio.com/"
]
}
]
},
{
"@id": "https://aulosbio.com/#breadcrumb",
"@type": "BreadcrumbList",
"itemListElement": [
{
"name": "Home",
"@type": "ListItem",
"position": 1
}
]
},
{
"@id": "https://aulosbio.com/#website",
"url": "https://aulosbio.com/",
"name": "Aulos Bioscience",
"@type": "WebSite",
"inLanguage": "en-US",
"description": "",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://aulosbio.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueName": "search_term_string",
"valueRequired": true
}
}
]
}
],
"@context": "https://schema.org/"
}
],
"phones": [],
"public": true,
"sha256": "94b88c5714779882f6b294de99a8565e9700223fb126088bd63700dac7704865",
"excerpt": " Revolutionizing cancer care through IL2 therapeutics | Aulos Bioscience Our Approach Overview Platform Abstracts and Publications Our Pipeline Overview About Us Overview Leadership Board of Directors Investors Corporate Presentation Mission and Values Newsroom Press Releases In the News Media Inquiries Videos Careers Join the Team Contact General Inquiries Search Our Approach Overview Platform Abstracts and Publications Our Pipeline Overview About Us Overview Leadership Board of Directors Investors Corporate Presentation Mission and Values Newsroom Press Releases In the News Media Inquiries Videos Careers Join the Team Contact General Inquiries Boosting Immunity and Restoring Hope Aulos ™ Bioscience is dedicated to helping people live longer, healthier lives. Its lead candidate, imneskibart (AU-007), is being developed to fight cancer in ways never before possible. LEARN MORE → A Fundamental Shift in Cancer Care At Aulos , we’re on a journey to revolutionize cancer patient care through the development of an immune-activating antibody therapeutic that we believe will transform the treatment of cancer. We’re taking on the toughest challenges in immuno-oncology by leveraging artificial intelligence to design a human monoclonal antibody that binds to the portion of interleukin-2 that interacts with the CD25 receptor subunit on regulatory T cells and the vasculature. We believe this therapeutic approach can shift IL-2 activity toward immune activation and away from immune suppression, and prevent the toxic side effects of IL-2, including vascular leak syndrome and pulmonary edema. LEARN MORE → Explore Our Science Our inventive scientific approach is designed to overcome past limitations in IL-2 therapy by combining precision, potency and safety to transform solid tumor treatment. Learn More Our Pipeline Imneskibart, our initial investigational product candidate, achieves what we believe no other IL-2 therapeutic in development does: tipping the balance toward immune activation. Learn More About Us We’re working with purpose to help patients live longer, guided by scientific rigor and motivated by a relentless commitment to advance bold medical solutions that change the course of cancer care. Learn More Abstracts and Publications Explore FEATURE Imneskibart + Low-Dose Subcutaneous IL-2 ± Nivolumab in Patients With CPI-Refractory Cutaneous Melanoma: Promising Results From an Ongoing Phase 1/2 Study Download PDF Latest News Recent Posts Aulos Bioscience to Present Phase 2 Data for Imneskibart With Avelumab in Adenocarcinoma Non-Small Cell Lung Cancer at ESMO Congress 2026 October 13, 2026 Aulos Bioscience Announces Presentations of Promising Phase 1/2 Data for Imneskibart With Checkpoint Inhibitors in Non-Small Cell Lung Cancer and Melanoma at SITC 2026 Annual Meeting October 2, 2026 View All → Imneskibart: An Investigational Product Candidate Aulos has initiated the Phase 2 portion of its Phase 1/2 clinical trial of imneskibart in patients with unresectable locally advanced or metastatic solid tumor cancers. The first expansion cohorts will focus on melanoma and renal cell carcinoma. LEARN MORE → Our novel therapeutic candidate is designed to exquisitely direct the body’s immune system to kill tumor cells by more safely and effectively unleashing the anti-cancer power of IL-2. LEARN MORE → AULOS BIOSCIENCE 700 LARKSPUR LANDING CIRCLE SUITE 108 LARKSPUR, CA 94939 LinkedIn twitter Our Approach Overview Platform Abstracts and Publications Our Pipeline Overview About Us Overview Leadership Board of Directors Investors Corporate Presentation Mission and Values Newsroom Press Releases In the News Media Inquiries Videos Careers Join the team Contact General Inquiries Terms of Use Privacy Social Media CA Compliance The Aulos name and logo are trademarks of Aulos Bioscience, Inc. © Copyright 2026 All Rights Reserved. ",
"source_url": "https://aulosbio.com/",
"observed_at": "2026-10-13T21:23:16.685Z"
}
}
],
"edges_out_total": 4
}